ArticleCancer discovery2025
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches.
Abstract read
In one paragraph
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression.Radiology and oncology · 2026Article
- CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.Nature communications · 2026Article
- Proteomic approaches for interrogating kinase signaling networks.The Journal of investigative dermatology · 2026Article
- Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods.NPJ precision oncology · 2025Article
- Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy.Molecular therapy. Oncology · 2025Article
- Experimental models of pancreas cancer: what has been the impact for precision medicine?The Journal of clinical investigation · 2025Review
- Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.The Journal of clinical investigation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Yi Xu *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0009-0003-6210-5289
Xianlu L Peng *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-8684-5762
Michael P EastDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-1994-6117
Ian C McCabeLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0009-0008-0655-238X
Grace C StromanDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0001-5465-9490
Madison R JennerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-3402-8509
Priscilla S ChanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0009-0000-4410-6542
Ashley B MorrisonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0009-0001-2219-0162
Emily C ShenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-8222-5144
Silvia G HererraLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0009-0006-2807-4601
Chinmaya U JoisaJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina.ORCID 0000-0001-5088-9598
Naim U RashidLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-7274-8259
Alina C IugaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-2351-8289
Shawn M GomezDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-8251-4552
Lisa Miller-PhillipsDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.ORCID 0009-0000-5368-4205
Stefan BoeckDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.ORCID 0000-0002-1922-2127
Volker HeinemannDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.ORCID 0000-0002-1349-3321
Michael HaasDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.ORCID 0000-0001-6745-7177
Steffen OrmannsGerman Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.ORCID 0000-0002-0754-9034
Gary L JohnsonDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-2867-0551
Jen Jen YehDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-2542-6211
Funding
Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6MSToP Cancer SPORE: Developmental Research ProgramP50CA257911 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jen Jen Yeh · 2022 to 2026
$12.9MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MIntegrating tumor and stroma to understand and predict treatment responseU01CA274298 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Naim Ur Rashid, Susan Tsai · 2022 to 2026
$4.7MPredictive Modeling of the EGFR-MAPK pathway for Triple Negative Breast Cancer PatientsU01CA238475 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ELSTON, TIMOTHY C, PEROU, CHARLES M · 2019 to 2023
$3.0MTargeted EGFR for basal subtype pancreatic cancerR01CA288145 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARY L. JOHNSON, Jen Jen Yeh · 2024 to 2026
$1.9MPathway, Network and Spatiotemporal Integration of Cancer Genomics DataU24CA264027 · NCI · PRINCETON UNIVERSITY · PI RAPHAEL, BENJAMIN, YEH, JEN JEN · 2021 to 2025
$1.5MNational Cancer Institute (NCI) P50CA257911National Cancer Institute (NCI) R01CA190644National Cancer Institute (NCI) T32CA071341National Cancer Institute (NCI) U24CA264027National Cancer Institute (NCI) U24DK116204NCI NIH HHS P50 CA257911NCI NIH HHS R01 CA288145NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA238475NCI NIH HHS U01 CA274298NCI NIH HHS U24 CA264027NIDDK NIH HHS U24 DK116204
Abstract
significanceWe provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.
Indexed as
Carcinoma, Pancreatic DuctalPancreatic NeoplasmsProtein Kinase InhibitorsHumansProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.